169 related articles for article (PubMed ID: 36891293)
1. Evaluation of multiple immune cells and patient outcomes in esophageal squamous cell carcinoma.
Wang H; Su C; Li Z; Ma C; Hong L; Li Z; Ma X; Xu Y; Wei X; Geng Y; Zhang W; Li P; Gu J
Front Immunol; 2023; 14():1091098. PubMed ID: 36891293
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.
Chen K; Zhu Z; Zhang N; Cheng G; Zhang F; Jin J; Wu J; Ying L; Mao W; Su D
Med Sci Monit; 2017 Sep; 23():4619-4632. PubMed ID: 28949934
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
[TBL] [Abstract][Full Text] [Related]
4. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma.
Wang J; Jia Y; Wang N; Zhang X; Tan B; Zhang G; Cheng Y
J Transl Med; 2014 Jan; 12():7. PubMed ID: 24397835
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma.
Yao Y; Xuan H; Wang J; Gong L; Gao W
Tumori; 2023 Oct; 109(5):466-480. PubMed ID: 37249074
[TBL] [Abstract][Full Text] [Related]
6. CD68 and interleukin 13, prospective immune markers for esophageal squamous cell carcinoma prognosis prediction.
Li J; Zhang BZ; Qin YR; Bi J; Liu HB; Li Y; Cai MY; Ma S; Chan KW; Xie D; Guan XY
Oncotarget; 2016 Mar; 7(13):15525-38. PubMed ID: 26771842
[TBL] [Abstract][Full Text] [Related]
7. Tertiary lymphoid structures correlate with enhancement of antitumor immunity in esophageal squamous cell carcinoma.
Nakamura S; Ohuchida K; Hayashi M; Katayama N; Tsutsumi C; Yamada Y; Hisano K; Okuda S; Ohtsubo Y; Iwamoto C; Torata N; Mizuuchi Y; Shindo K; Nakata K; Moriyama T; Morisaki T; Oda Y; Nakamura M
Br J Cancer; 2023 Oct; 129(8):1314-1326. PubMed ID: 37604932
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma.
Duan H; Zhang X; Wang FX; Cai MY; Ma GW; Yang H; Fu JH; Tan ZH; Meng YQ; Fu XY; Ma QL; Lin P
World J Gastroenterol; 2015 May; 21(18):5591-7. PubMed ID: 25987784
[TBL] [Abstract][Full Text] [Related]
9. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma.
Lv L; Pan K; Li XD; She KL; Zhao JJ; Wang W; Chen JG; Chen YB; Yun JP; Xia JC
PLoS One; 2011 Mar; 6(3):e18219. PubMed ID: 21483813
[TBL] [Abstract][Full Text] [Related]
10. The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma.
Wang J; Tian S; Sun J; Zhang J; Lin L; Hu C
BMC Cancer; 2020 Aug; 20(1):731. PubMed ID: 32758195
[TBL] [Abstract][Full Text] [Related]
11. Low expression of PRDM5 predicts poor prognosis of esophageal squamous cell carcinoma.
Guo J; Yang Q; Wei S; Shao J; Zhao T; Guo L; Liu J; Chen J; Wang G
BMC Cancer; 2022 Jul; 22(1):745. PubMed ID: 35799142
[TBL] [Abstract][Full Text] [Related]
12. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma.
Cho Y; Miyamoto M; Kato K; Fukunaga A; Shichinohe T; Kawarada Y; Hida Y; Oshikiri T; Kurokawa T; Suzuoki M; Nakakubo Y; Hiraoka K; Murakami S; Shinohara T; Itoh T; Okushiba S; Kondo S; Katoh H
Cancer Res; 2003 Apr; 63(7):1555-9. PubMed ID: 12670904
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma.
Fang J; Li X; Ma D; Liu X; Chen Y; Wang Y; Lui VWY; Xia J; Cheng B; Wang Z
BMC Cancer; 2017 May; 17(1):375. PubMed ID: 28549420
[TBL] [Abstract][Full Text] [Related]
14. High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma.
Abudureheman A; Ainiwaer J; Hou Z; Niyaz M; Turghun A; Hasim A; Zhang H; Lu X; Sheyhidin I
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1025-1035. PubMed ID: 29532228
[TBL] [Abstract][Full Text] [Related]
15. Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer.
He JZ; Chen Y; Zeng FM; Huang QF; Zhang HF; Wang SH; Yu SX; Pang XX; Liu Y; Xu XE; Wu JY; Shen WJ; Li ZY; Li EM; Xu LY
J Exp Clin Cancer Res; 2023 May; 42(1):136. PubMed ID: 37254126
[TBL] [Abstract][Full Text] [Related]
16. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
[TBL] [Abstract][Full Text] [Related]
17. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.
Wang J; Wu N; Zheng QF; Yan S; Lv C; Li SL; Yang Y
World J Gastroenterol; 2014 Dec; 20(48):18397-403. PubMed ID: 25561808
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of Fn-induced high expression of KIR2DL1 in CD8 T lymphocytes in oesophageal squamous cell carcinoma.
Wang X; Liu Y; Lu Y; Chen S; Xing Y; Yang H; Wang X; Zhang Y; Pan T; Li J; Wang M; Zhang N; Liang M; Zhou F
Ann Med; 2022 Dec; 54(1):51-62. PubMed ID: 34935568
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.
Hatogai K; Kitano S; Fujii S; Kojima T; Daiko H; Nomura S; Yoshino T; Ohtsu A; Takiguchi Y; Doi T; Ochiai A
Oncotarget; 2016 Jul; 7(30):47252-47264. PubMed ID: 27322149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
